STAREE Trial: Atorvastatin Cuts Heart Events in Seniors but Fails to Boost Disability-Free Survival

Key points

• The STAREE trial involved 9,971 participants aged 70+ without prior cardiovascular disease, diabetes, or dementia.
• Atorvastatin 40 mg daily reduced the risk of major cardiovascular events (death, MI, stroke, revascularization) by 30% compared to placebo.
• The trial failed to show a significant improvement in the secondary endpoint of disability-free survival, which includes freedom from dementia and physical disability.
• The study addresses a gap in previous trials that underrepresented older adults without known cardiovascular conditions.
• Results were presented at ESC Congress 2026 and published in the New England Journal of Medicine.

Background

Previous coverage noted that while statins are widely prescribed for cholesterol management, their risk-benefit profile for primary prevention in older adults without existing cardiovascular disease had been uncertain due to limited data. This trial provides the first large randomized controlled evidence for this specific demographic, complementing broader discussions on LDL targets and alternative lipid-lowering therapies like inclisiran.

Why it matters

The findings clarify the utility of statins for primary prevention in healthy older adults, showing clear cardiovascular benefits without necessarily extending healthy, disability-free life, which informs clinical guidelines for this growing population.

What to watch

Clinicians may use these results to guide statin prescriptions for primary prevention in healthy seniors, while further research is needed to understand why disability-free survival did not improve despite reduced cardiovascular events.